Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Inherited cancer--concept and classification]

T Abe¹, S Horiike

¹Department of Hygiene, Kyoto Prefectural University of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|November 1, 1995

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cytogenetic and molecular abnormalities in myelodysplastic syndrome.

Current molecular medicine·2011

Same author

Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.

Leukemia·2010

Same author

Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C.

British journal of cancer·2008

Same author

Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.

Journal of viral hepatitis·2006

Same author

Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.

Journal of viral hepatitis·2006

Same author

Multiple bone lesions after allogeneic bone marrow transplantation in a patient with relapsed adult acute lymphoblastic leukemia: minimal residual disease analysis may predict extramedullary relapse.

Leukemia & lymphoma·2002

Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019

Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019

See all related articles

This review covers hereditary cancer syndromes and inherited diseases increasing cancer risk, focusing on recent classifications. It discusses the roles of tumor suppressor genes and oncogenes in disease development.

Area of Science:

Genetics
Oncology
Molecular Biology

Context:

Hereditary cancer syndromes represent a significant portion of cancer diagnoses.
Understanding the genetic basis of these syndromes is crucial for risk assessment and prevention.
Recessively inherited diseases can also confer an increased predisposition to cancer.

Purpose:

To review the current concepts and classifications of hereditary cancer syndromes.
To explore the role of tumor suppressor genes and oncogenes in the pathogenesis of these conditions.
To provide an updated overview of the genetic landscape of inherited cancer predisposition.

Summary:

This review synthesizes recent advancements in the understanding and classification of hereditary cancer syndromes.

Related Experiment Videos

It highlights the involvement of key genetic players, including tumor suppressor genes and oncogenes, in cancer development.

The discussion encompasses recessively inherited diseases that contribute to cancer predisposition.

Impact:

Provides a consolidated resource for researchers and clinicians on hereditary cancer genetics.
Facilitates improved diagnostic strategies and genetic counseling for families at risk.
Contributes to the development of targeted therapies based on specific genetic alterations.